Ratings i-SENS, Inc.

Equities

A099190

KR7099190001

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
19,120 ^KRW	+0.31%		+4.20%	-33.15%

Apr. 26	I-SENS, Inc. announced that it expects to receive KRW 50 billion in funding from NH Investment & Securities Co., Ltd., Atinum Investment Co., Ltd	CI
Mar. 20	I-SENS, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Strengths

Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Over the past twelve months, analysts' opinions have been strongly revised upwards.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

The valuation of the company is particularly high given the cash flows generated by its activity.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
I-SENS, INC.	-33.15%	382M	-
SHOCKWAVE MEDICAL, INC.	+73.17%	12.34B	B-
PENUMBRA, INC.	-18.74%	7.96B	C+
MASIMO CORPORATION	+16.15%	7.16B	C-
GETINGE AB	+4.81%	5.72B	B
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.	+5.99%	5.03B	D+
APT MEDICAL INC.	+27.07%	4.35B	-
ASAHI INTECC CO., LTD.	-21.67%	3.99B	B-
INARI MEDICAL, INC.	-40.82%	2.21B	C
SKAN GROUP AG	+1.49%	2.01B	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes